{"id":"anti-cd-25-mab-sirolimus-mmf","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Thrombocytopenia"},{"rate":"10-20%","effect":"Leukopenia"},{"rate":"5-10%","effect":"Anemia"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This mechanism is based on the principle of immunosuppression, where the drug inhibits the activation of T cells, which play a key role in the immune response. By targeting CD25, a protein expressed on activated T cells, the drug reduces the immune response and prevents the rejection of transplanted organs or the progression of autoimmune diseases.","oneSentence":"Anti-CD 25 mAb targets and binds to the CD25 receptor on T cells, preventing their activation and proliferation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:01:52.360Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in kidney transplant patients"},{"name":"Treatment of graft-versus-host disease"}]},"trialDetails":[{"nctId":"NCT00604357","phase":"PHASE3","title":"CNI-free de Novo Protocol in Patients Undergoing Liver Transplantation With Renal Impairment","status":"COMPLETED","sponsor":"University of Regensburg","startDate":"2008-12","conditions":"End Stage Liver Disease, Impaired Renal Function","enrollment":27}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Rapamune","Simulect","CellCept","DecortinH"],"phase":"phase_3","status":"active","brandName":"anti-CD 25 mAb, Sirolimus, MMF","genericName":"anti-CD 25 mAb, Sirolimus, MMF","companyName":"University of Regensburg","companyId":"university-of-regensburg","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anti-CD 25 mAb targets and binds to the CD25 receptor on T cells, preventing their activation and proliferation. Used for Prevention of organ rejection in kidney transplant patients, Treatment of graft-versus-host disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}